More than 300 executives from biotech and pharmaceutical companies have signed an open letter opposing a Texas judge’s decision to stop mifepristone, the commonly used abortion pill, from being sold, Reuters’ Michael Erman and Ahmed Aboulenein report. The CEO of pharma giant Pfizer (PFE), Albert Bourla, signed the letter, along with many other biotech companies, including Biogen (BIIB) and Ovid Therapeutics (OVID). A U.S. judge on Friday suspended the U.S. FDA’s 2000 approval of the drug. "We call for the reversal of this decision to disregard science, and the appropriate restitution of the mandate for the safety and efficacy of medicines for all with the FDA, the agency entrusted to do so in the first place," the executives wrote. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer price target lowered to $44 from $45 at Morgan Stanley
- Arbutus, Genevant file patent infringement suit against Pfizer, BioNTech
- Padcev combo approval should alleviate concerns on Seagen deal, says BofA
- Pfizer: FDA accepts sNDAs for BRAFTOVI + MEKTOVI
- BioCryst appoints Hutson as Chair of the Board